Adam Feuerstein

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

 


Feuerstein graduated from Emory University with a bachelor's degree in political science.

 


Recent Articles By The Author

Biogen Shares Spike on Leaked Alzheimer's Drug Data

Biogen Shares Spike on Leaked Alzheimer's Drug Data

Shares are Biogen spiked on the aducanumab data leak as investors with unfair access to what was supposed to be embargoed results traded on the information.

Voyager Gene Therapy Shows Early, Promising Motor Function Improvements for Parkinson's Patients

Voyager Gene Therapy Shows Early, Promising Motor Function Improvements for Parkinson's Patients

Voyager's gene therapy aims to turn back the clock so advanced Parkinson's patients respond better and longer to the standard drug used to treat the brain disease.

Cascadian Therapeutics Enlarges Breast Cancer Pill Study to Meet FDA Registration Standards

Cascadian Therapeutics Enlarges Breast Cancer Pill Study to Meet FDA Registration Standards

Cascadian's tucatinib delays regrowth of breast cancer by a median of 7.8 months in newly updated study results presented this week.

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting

I spent the weekend with thousands of blood disease researchers. This is what happened.

Patient Deaths, Safety Concerns Cause Juno's CAR-T Pipeline to Skid Out

Patient Deaths, Safety Concerns Cause Juno's CAR-T Pipeline to Skid Out

Juno now finds itself one year, if not two years or more, behind rivals Novartis and Kite.